Published in AIDS Weekly, July 8th, 1996
The increasing incidence of renal dysfunction among HIV positive patients prompted Heald to examine the safety and pharmacokinetics of lamivudine in 16 HIV positive patients - six with normal renal function, four with moderate renal impairment and six with severe renal impairment. She found that the "... peak concentration of 3TC [lamivudine] increased with decreasing renal function," (Antimicrob Agents & Chemo 1996;40:1514-1519).
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.